[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![Quantumup1 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1060595604022280192.png) quantumup [@Quantumup1](/creator/twitter/Quantumup1) on x 3537 followers
Created: 2025-07-23 11:57:30 UTC

Citizens⬆️ $ABVX PT to $XX from $33, reiterated at a Market Outperform and said, "Stellar Phase X results for obefazimod in ulcerative colitis support potential for broad and early use in clinical practice"
$ABBV $BMY $PFE $TAK $JNJ
 $PTGX - $JNJ $VYTX $LLY
Guggenheim⬆️ $ABVX PT to $XXX from $50, reiterated Buy and said the data clearly beat its and the Buyside's expectations — believes obe S/B valued $7-10B range, given the recent M&A comps — Gugg's KOL called data "striking"

Citizens said, "we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $XX from $XX on Abivax SA.
Yesterday afternoon, Abivax announced positive results from the two Phase X induction trials for obefazimod in moderate-to-severe ulcerative colitis.

 We view the results as highly compelling, with a pooled, placebo-adjusted clinical remission rate of XXXX% (p<0.0001) and a clean safety/tolerability profile. We raise our probability of approval and sales projections for the candidate, driving our increased price target."

Guggenheim in its note said:

![](https://pbs.twimg.com/media/Gwij5DcXQAAJmib.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947989444595777552/c:line.svg)

**Related Topics**
[$lly](/topic/$lly)
[$vytx](/topic/$vytx)
[$jnj](/topic/$jnj)
[$tak](/topic/$tak)
[$abvx](/topic/$abvx)
[$abbv](/topic/$abbv)
[stocks healthcare](/topic/stocks-healthcare)
[$bmy](/topic/$bmy)

[Post Link](https://x.com/Quantumup1/status/1947989444595777552)